- Policy
- Reimb criteria established for Roche's DLBCL drug 'Polivy'
- by Lee, Tak-Sun Jul 25, 2025 06:08am
- The reimbursement criteria for Roche Korea's Polivy (polatuzumab vedotin), a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), have been successfully established by the Health Insurance Review & Assessment Service's (HIRA) Cancer Disease Review Committee (CDRC). This drug, which is garnering attention as the first DL
- Policy
- Eun-Kyung Jeong appointed as new MOHW Minister
- by Lee, Jeong-Hwan Jul 24, 2025 11:38pm
- With the appointment of Eun-kyung&160; Jeong (60, Seoul National University College of Medicine) as Minister of Health and Welfare, efforts to institutionalize and legislate telemedicine, as well as to establish a prescription drug delivery system, are expected to gain momentum. The government will begin establishing specific measures to
- Policy
- Jeong Eun-kyung views "orphan disease fund establishment"
- by Lee, Jeong-Hwan Jul 24, 2025 11:38pm
- Jung Eun-kyung, the candidate for Minister of Health and Welfare (MOHW), has expressed skepticism regarding the establishment of a separate fund to improve the National Health Insurance reimbursement rate for treatments for expensive, rare (orphan), and severe diseases. The rationale is that if the required financial scale for reimbursing
- Policy
- Release of Boryung’s generic version of Stivarga imminent
- by Lee, Tak-Sun Jul 24, 2025 06:07am
- The price of the liver cancer drug Stivarga Tab 40mg (regorafenib, Bayer) will be adjusted following the termination of the risk-sharing agreement due to the anticipated listing of its generic versions. Among the many companies, Boryung is expected to be the first company to launch a generic version of Stivarga in Korea. According to
- Policy
- Ruling party introduces another bill to reimburse abortion
- by Lee, Jeong-Hwan Jul 24, 2025 06:07am
- Following Representative In-soon Nam of the Democratic Party of Korea, Representative Sujin Lee of the same party submitted a bill on the 23rd to legally allow artificial termination of pregnancy through drugs such as Mifegyne and to apply health insurance reimbursement to surgical and pharmaceutical abortion procedures. The partial amend
- Policy
- Supply shortage of Parkinson’s drug Equfina is expected
- by Lee, Hye-Kyung Jul 23, 2025 06:08am
- Eisai Korea's Parkinson's disease treatment ‘Equfina Film-Coated Tab 50mg (safinamide mesilate)’ is expected to be in short supply for the next month, causing inconvenience to patients. In particular, although there are drugs with similar efficacy to Equfina, there are no direct therapeutic substitutes available with the same ingredie
- Policy
- Jardiance 10mg price reduced from ₩618 to ₩582
- by Lee, Tak-Sun Jul 21, 2025 06:06am
- The maximum insurance price ceiling for the 10 mg flagship dosage form of the SGLT-2 inhibitor diabetes treatment Jardiance Tab (empagliflozin, Boehringer Ingelheim), will be adjusted as reimbursement will also apply to chronic kidney disease.&160; Jardiance recorded KRW 66.3 billion in outpatient prescriptions (based on UBIST) last year
- Policy
- [Reporter's View] A separate fund for new orphan drugs
- by Lee, Jeong-Hwan Jul 18, 2025 06:36am
- Will the 'establishment of a separate fund,' considered one of the ways to improve patient access to expensive, rare, and intractable disease drugs, become even more difficult with the inauguration of the Lee Jae Myung administration? Jung Eun-kyung, the candidate for Minister of Health and Welfare (MOHW), who is facing a parliamentary co
- Policy
- Will the external reference pricing reevals gain momentum?
- by Lee, Jeong-Hwan Jul 18, 2025 06:35am
- Eun-Kyung Jeong, nominee for Minister of Health and Welfare, said that “it is important to manage drug prices at an appropriate level given the limited health insurance resources” regarding the post-marketing price review system to lower generic drug prices through “external reference pricing evaluations,” suggesting the possibility of i
- Policy
- When will Keytruda’s reimb be reviewed by DREC?
- by Lee, Tak-Sun Jul 17, 2025 06:13am
- Attention is focused on when Keytruda, for which reimbursement standards were set for 11 indications in February, will be submitted to the Drug Reimbursement Evaluation Committee (DREC) for review. This is because, although the reimbursement standards were established by the Health Insurance Review and Assessment Service's Cancer Review C
